alogliptin (nesina) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Alogliptin (trade name Nesina in the US and Vipidia in Europe) is an orally administered anti-diabetic drug in the DPP-4 inhibitor class, discovered by Takeda Pharmaceutical Company's wholly owned subsidiary, Takeda San Diego, Inc. (former Syrrx) which was acquired by Takeda in 2005. Alogliptin does not decrease the risk of heart attack and stroke. Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of causing hypoglycemia, and exhibits relatively modest glucose-lowering activity. Alogliptin and other gliptins are commonly used in combination with metformin in patients whose diabetes cannot adequately be controlled with metformin alone.   NCATS

Chemistry

  • SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(Cc3ccccc3C#N)C1=O
  • InChIKey: ZSBOMTDTBDDKMP-OAHLLOKOSA-N
  • Mol. Mass: 339.4
  • ALogP: 0.39
  • ChEMBL Molecules:
    alogliptin  
    alogliptin benzoate  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.5300 - $13.0428

Australia

$1.2540
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

2-((6-((3r)-3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)methyl) benzonitrile | alogliptin | alogliptina | alogliptin benzoate | alogliptin benzoate / metformin hydrochloride | alogliptine | alogliptin / metformin | alogliptin / pioglitazone | alogliptinum | nesina | syr322 | syr 322 | syr-322 | vipdomet | vipidia

Organizations (20)

Research & Development (17)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (9)

Approved Indications (1)


 

Diabetes Mellitus, Type 2

Experimental Indications - Clinical Trial Phases 1-4 (9)


 

Acute Coronary Syndrome (Phase 3)

Diabetes Mellitus ()

Diabetes Mellitus, Type 2 ()

Healthy Volunteers (Phase 1)

Insulin Resistance (Phase 4)

Non-alcoholic Fatty Liver Disease (Phase 4)

Pharmacokinetics (Phase 1)

Pharmacology, Clinical (Phase 3)

Polycystic Ovary Syndrome (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 59
  • # of Trial Organizations: 17

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue